

## ETHIOPIA – PENTAVALENT VACCINE SUPPORT

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Ethiopia			
<b>2. Grant Number:</b> 0715-ETH-04a-X			
<b>3. Date of Decision Letter:</b> 19 December 2014			
<b>4. Date of the Partnership Framework Agreement:</b> 23 July 2013			
<b>5. Programme Title:</b> New Vaccine Support			
<b>6. Vaccine type:</b> Pentavalent			
<b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 1 dose(s) per vial, LIQUID			
<b>8. Programme Duration<sup>1</sup>:</b> 2007 - 2015			
<b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b>			
	2007-2014	2015	Total <sup>2</sup>
Programme Budget (US\$)	US\$202,039,194 <sup>3</sup>	US\$11,813,000	US\$213,852,194
<b>10. Vaccine Introduction Grant:</b> Not applicable			
<b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>4</sup></b>			
Type of supplies to be purchased with GAVI funds in each year	2007-2014	2015	
Number of Pentavalent vaccines doses		5,784,400	
Number of AD syringes		6,646,900	
Number of safety boxes		73,125	
Annual Amounts (US\$)	US\$202,039,194 <sup>5</sup>	US\$11,813,000	
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payment each year to UNICEF.			

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the amount that GAVI has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years.

<b>13. Self-procurement:</b> Not applicable.	
<b>14. Co-financing obligations:</b> Reference code: 0715-ETH-04a-X-C	
According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.	
Type of supplies to be purchased with Country funds in each year	2015
Number of vaccine doses	650,700
Value of vaccine doses (US\$)	US\$1,244,717
Total Co-Financing Payments (US\$) (including freight)	US\$1,287,500
<b>15. Operational support for campaigns:</b> Not applicable	
<b>16. Additional documents to be delivered for future disbursements:</b>	
Reports, documents and other deliverables	Due dates
Annual Progress Report or its equivalent	15 May 2015
<b>17. Financial Clarifications:</b> Not applicable	
<b>18. Other conditions:</b> Not applicable	

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
19 December 2014

## ETHIOPIA - PNEUMOCOCCAL VACCINE SUPPORT

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Ethiopia					
<b>2. Grant Number:</b> 1517-ETH-12b-X					
<b>3. Date of Decision Letter:</b> 19 December 2014					
<b>4. Date of the Partnership Framework Agreement:</b> 23 July 2013					
<b>5. Programme Title:</b> New Vaccine Support					
<b>6. Vaccine type:</b> Pneumococcal					
<b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV10), 2 dose(s) per vial, LIQUID					
<b>8. Programme Duration<sup>1</sup>:</b> 2011 - 2017					
<b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b>					
	2011-2014	2015	2016	2017	Total <sup>2</sup>
Programme Budget (US\$)	US\$205,739,319 <sup>3</sup>	US\$36,471,000	US\$31,371,500	US\$39,302,500	US\$312,884,319
<b>10. Vaccine Introduction Grant:</b> Not applicable.					
<b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>4</sup></b>					
Type of supplies to be purchased with GAVI funds in each year	2011-2014	2015			
Number of Pneumococcal vaccines doses		8,849,200			
Number of AD syringes		9,307,400			
Number of safety boxes		102,400			
Annual Amounts (US\$)	US\$205,739,319 <sup>5</sup>	US\$36,471,000			
<b>12. Procurement agency:</b> UNICEF					

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the amount that GAVI has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years.

<b>13. Self-procurement:</b> Not applicable			
<b>14. Co-financing obligations:</b> Reference code: 1517-ETH-12b-X-C			
According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.			
Type of supplies to be purchased with Country funds in each year	<b>2015</b>	<b>2016</b>	<b>2017</b>
Number of vaccine doses	540,800	537,200	549,200
Value of vaccine doses (US\$)	US\$1,823,943		
Total Co-Financing Payments (US\$) (including freight)	US\$1,878,000	US\$1,874,500	US\$1,874,500
<b>15. Operational support for campaigns:</b> n/a			
<b>16. Additional documents to be delivered for future disbursements:</b>			
Reports, documents and other deliverables		Due dates	
Annual Progress Report or its equivalent		15 May 2015	
<b>17. Financial Clarifications:</b> Not applicable			
<b>18. Other conditions:</b> Not applicable			

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
19 December 2014

## ETHIOPIA – ROTAVIRUS VACCINE SUPPORT

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Ethiopia			
<b>2. Grant Number:</b> 1215-ETH-13b-X			
<b>3. Date of Decision Letter:</b> 19 December 2014			
<b>4. Date of the Partnership Framework Agreement:</b> 23 July 2013			
<b>5. Programme Title:</b> New Vaccine Support			
<b>6. Vaccine type:</b> Rotavirus			
<b>7. Requested product presentation and formulation of vaccine:</b> Rotavirus, 2 dose(s) schedule			
<b>8. Programme Duration<sup>1</sup>:</b> 2013 - 2015			
<b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b>			
	2013-2014	2015	Total <sup>2</sup>
Programme Budget (US\$)	US\$20,583,281 <sup>3</sup>	US\$13,686,500	US\$34,269,781
<b>10. Vaccine Introduction Grant:</b> Not applicable			
<b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>4</sup></b>			
Type of supplies to be purchased with GAVI funds in each year	2013-2014	2015	
Number of Rotavirus vaccines doses		5,142,000	
Annual Amounts (US\$)	US\$20,583,281 <sup>5</sup>	US\$13,686,500	
<b>12. Procurement agency:</b> UNICEF			
<b>13. Self-procurement:</b> Not applicable.			

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the amount that GAVI has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years.

**14. Co-financing obligations: Reference code: 1215-ETH-13b-X-C**

According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2015
Number of vaccine doses	418,500
Value of vaccine doses (US\$)	US\$1,070,313
Total Co-Financing Payments (US\$) (including freight)	US\$1,112,500

**15. Operational support for campaigns: n/a**

**16. Additional documents to be delivered for future disbursements:**

Reports, documents and other deliverables	Due dates
Annual Progress Report or its equivalent	15 May 2015

**17. Financial Clarifications: Not applicable**

**18. Other conditions: Not applicable**

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
19 December 2014